Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study.

Long GV, Dummer R, Hamid O, Gajewski TF, Caglevic C, Dalle S, Arance A, Carlino MS, Grob JJ, Kim TM, Demidov L, Robert C, Larkin J, Anderson JR, Maleski J, Jones M, Diede SJ, Mitchell TC.

Lancet Oncol. 2019 Jun 17. pii: S1470-2045(19)30274-8. doi: 10.1016/S1470-2045(19)30274-8. [Epub ahead of print]

PMID:
31221619
2.

TOX transcriptionally and epigenetically programs CD8+ T cell exhaustion.

Khan O, Giles JR, McDonald S, Manne S, Ngiow SF, Patel KP, Werner MT, Huang AC, Alexander KA, Wu JE, Attanasio J, Yan P, George SM, Bengsch B, Staupe RP, Donahue G, Xu W, Amaravadi RK, Xu X, Karakousis GC, Mitchell TC, Schuchter LM, Kaye J, Berger SL, Wherry EJ.

Nature. 2019 Jun 17. doi: 10.1038/s41586-019-1325-x. [Epub ahead of print]

PMID:
31207603
3.

Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma.

Gibney GT, Hamid O, Lutzky J, Olszanski AJ, Mitchell TC, Gajewski TF, Chmielowski B, Hanks BA, Zhao Y, Newton RC, Maleski J, Leopold L, Weber JS.

J Immunother Cancer. 2019 Mar 20;7(1):80. doi: 10.1186/s40425-019-0562-8.

4.

A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma.

Huang AC, Orlowski RJ, Xu X, Mick R, George SM, Yan PK, Manne S, Kraya AA, Wubbenhorst B, Dorfman L, D'Andrea K, Wenz BM, Liu S, Chilukuri L, Kozlov A, Carberry M, Giles L, Kier MW, Quagliarello F, McGettigan S, Kreider K, Annamalai L, Zhao Q, Mogg R, Xu W, Blumenschein WM, Yearley JH, Linette GP, Amaravadi RK, Schuchter LM, Herati RS, Bengsch B, Nathanson KL, Farwell MD, Karakousis GC, Wherry EJ, Mitchell TC.

Nat Med. 2019 Mar;25(3):454-461. doi: 10.1038/s41591-019-0357-y. Epub 2019 Feb 25.

PMID:
30804515
5.

Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.

Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph R, Weber JS, Dronca R, Mitchell TC, Patnaik A, Zarour HM, Joshua AM, Zhao Q, Jensen E, Ahsan S, Ibrahim N, Ribas A.

Ann Oncol. 2019 Apr 1;30(4):582-588. doi: 10.1093/annonc/mdz011.

6.

ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma.

Ojha R, Leli NM, Onorati A, Piao S, Verginadis II, Tameire F, Rebecca VW, Chude CI, Murugan S, Fennelly C, Noguera-Ortega E, Liu S, Xu X, Krepler C, Xiao M, Xu W, Wei Z, Frederick DT, Boland G, Mitchell TC, Karakousis GC, Schuchter LM, Flaherty KT, Zhang G, Herlyn M, Koumenis C, Amaravadi RK.

Cancer Discov. 2019 Mar;9(3):396-415. doi: 10.1158/2159-8290.CD-18-0348. Epub 2018 Dec 18.

PMID:
30563872
7.

Physiologic colonic fluorine-18-fluorodeoxyglucose uptake may predict response to immunotherapy in patients with metastatic melanoma.

Boursi B, Werner TJ, Gholami S, Margalit O, Baruch E, Markel G, Eshet Y, Houshmand S, Shacham-Shmueli E, Mitchell TC, Mamtani R, Alavi A, Yang YX.

Melanoma Res. 2019 Jun;29(3):318-321. doi: 10.1097/CMR.0000000000000566.

PMID:
30557217
8.

A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours.

Maity A, Mick R, Huang AC, George SM, Farwell MD, Lukens JN, Berman AT, Mitchell TC, Bauml J, Schuchter LM, O'Hara M, Lin LL, Demichele A, Christodouleas JP, Haas NB, Patsch DM, Hahn SM, Minn AJ, Wherry EJ, Vonderheide RH.

Br J Cancer. 2018 Nov;119(10):1200-1207. doi: 10.1038/s41416-018-0281-9. Epub 2018 Oct 15.

PMID:
30318516
9.

Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037).

Mitchell TC, Hamid O, Smith DC, Bauer TM, Wasser JS, Olszanski AJ, Luke JJ, Balmanoukian AS, Schmidt EV, Zhao Y, Gong X, Maleski J, Leopold L, Gajewski TF.

J Clin Oncol. 2018 Sep 28:JCO2018789602. doi: 10.1200/JCO.2018.78.9602. [Epub ahead of print]

10.

Immunotherapy in melanoma.

Feld E, Mitchell TC.

Immunotherapy. 2018 Aug;10(11):987-998. doi: 10.2217/imt-2017-0143.

PMID:
30149766
11.

Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response.

Chen G, Huang AC, Zhang W, Zhang G, Wu M, Xu W, Yu Z, Yang J, Wang B, Sun H, Xia H, Man Q, Zhong W, Antelo LF, Wu B, Xiong X, Liu X, Guan L, Li T, Liu S, Yang R, Lu Y, Dong L, McGettigan S, Somasundaram R, Radhakrishnan R, Mills G, Lu Y, Kim J, Chen YH, Dong H, Zhao Y, Karakousis GC, Mitchell TC, Schuchter LM, Herlyn M, Wherry EJ, Xu X, Guo W.

Nature. 2018 Aug;560(7718):382-386. doi: 10.1038/s41586-018-0392-8. Epub 2018 Aug 8.

12.

A GRIM fate for human neutrophils in airway disease.

Mitchell TC.

J Leukoc Biol. 2018 Oct;104(4):657-659. doi: 10.1002/JLB.5CE0418-162R. Epub 2018 Aug 1. No abstract available.

PMID:
30066961
13.

Timing of Onset of Adverse Cutaneous Reactions Associated With Programmed Cell Death Protein 1 Inhibitor Therapy.

Wang LL, Patel G, Chiesa-Fuxench ZC, McGettigan S, Schuchter L, Mitchell TC, Ming ME, Chu EY.

JAMA Dermatol. 2018 Sep 1;154(9):1057-1061. doi: 10.1001/jamadermatol.2018.1912.

PMID:
30027278
14.

Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma.

Tetzlaff MT, Messina JL, Stein JE, Xu X, Amaria RN, Blank CU, van de Wiel BA, Ferguson PM, Rawson RV, Ross MI, Spillane AJ, Gershenwald JE, Saw RPM, van Akkooi ACJ, van Houdt WJ, Mitchell TC, Menzies AM, Long GV, Wargo JA, Davies MA, Prieto VG, Taube JM, Scolyer RA.

Ann Oncol. 2018 Aug 1;29(8):1861-1868. doi: 10.1093/annonc/mdy226.

PMID:
29945191
15.

Pembrolizumab-induced sarcoidal infusion site reaction.

Smith RJ, Mitchell TC, Chu EY.

J Cutan Pathol. 2018 Jun 25. doi: 10.1111/cup.13307. [Epub ahead of print] No abstract available.

PMID:
29938827
16.

Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma.

Zhang G, Wu LW, Mender I, Barzily-Rokni M, Hammond MR, Ope O, Cheng C, Vasilopoulos T, Randell S, Sadek N, Beroard A, Xiao M, Tian T, Tan J, Saeed U, Sugarman E, Krepler C, Brafford P, Sproesser K, Murugan S, Somasundaram R, Garman B, Wubbenhorst B, Woo J, Yin X, Liu Q, Frederick DT, Miao B, Xu W, Karakousis GC, Xu X, Schuchter LM, Mitchell TC, Kwong LN, Amaravadi RK, Lu Y, Boland GM, Wei Z, Nathanson K, Herbig U, Mills GB, Flaherty KT, Herlyn M, Shay JW.

Clin Cancer Res. 2018 Oct 1;24(19):4771-4784. doi: 10.1158/1078-0432.CCR-17-2773. Epub 2018 Mar 21.

PMID:
29563139
17.

Mast Cell-Dependent CD8+ T-cell Recruitment Mediates Immune Surveillance of Intestinal Tumors in ApcMin/+ Mice.

Bodduluri SR, Mathis S, Maturu P, Krishnan E, Satpathy SR, Chilton PM, Mitchell TC, Lira S, Locati M, Mantovani A, Jala VR, Haribabu B.

Cancer Immunol Res. 2018 Jan 30. doi: 10.1158/2326-6066.CIR-17-0424. [Epub ahead of print]

PMID:
29382671
18.

No pain no gain? Adjuvant effects of alum and monophosphoryl lipid A in pertussis and HPV vaccines.

Mitchell TC, Casella CR.

Curr Opin Immunol. 2017 Aug;47:17-25. doi: 10.1016/j.coi.2017.06.009. Epub 2017 Jul 17. Review.

19.

A Pseudomonas aeruginosa hepta-acylated lipid A variant associated with cystic fibrosis selectively activates human neutrophils.

SenGupta S, Hittle LE, Ernst RK, Uriarte SM, Mitchell TC.

J Leukoc Biol. 2016 Nov;100(5):1047-1059. Epub 2016 Aug 18.

PMID:
27538572
20.

How the temperate world was colonised by bindweeds: biogeography of the Convolvuleae (Convolvulaceae).

Mitchell TC, Williams BR, Wood JR, Harris DJ, Scotland RW, Carine MA.

BMC Evol Biol. 2016 Jan 19;16:16. doi: 10.1186/s12862-016-0591-6.

21.

A foundation monograph of Convolvulus L. (Convolvulaceae).

Wood JR, Williams BR, Mitchell TC, Carine MA, Harris DJ, Scotland RW.

PhytoKeys. 2015 Jun 18;(51):1-282. doi: 10.3897/phytokeys.51.7104. eCollection 2015.

22.

Type I interferon signaling contributes to the bias that Toll-like receptor 4 exhibits for signaling mediated by the adaptor protein TRIF.

Kolb JP, Casella CR, SenGupta S, Chilton PM, Mitchell TC.

Sci Signal. 2014 Nov 11;7(351):ra108. doi: 10.1126/scisignal.2005442.

23.

Dietary iron controls circadian hepatic glucose metabolism through heme synthesis.

Simcox JA, Mitchell TC, Gao Y, Just SF, Cooksey R, Cox J, Ajioka R, Jones D, Lee SH, King D, Huang J, McClain DA.

Diabetes. 2015 Apr;64(4):1108-19. doi: 10.2337/db14-0646. Epub 2014 Oct 14.

24.

Adjuvant activity of naturally occurring monophosphoryl lipopolysaccharide preparations from mucosa-associated bacteria.

Chilton PM, Hadel DM, To TT, Mitchell TC, Darveau RP.

Infect Immun. 2013 Sep;81(9):3317-25. doi: 10.1128/IAI.01150-12. Epub 2013 Jun 24.

25.

Inefficient TLR4/MD-2 heterotetramerization by monophosphoryl lipid A.

Casella CR, Mitchell TC.

PLoS One. 2013 Apr 26;8(4):e62622. doi: 10.1371/journal.pone.0062622. Print 2013.

26.

Iron regulates glucose homeostasis in liver and muscle via AMP-activated protein kinase in mice.

Huang J, Simcox J, Mitchell TC, Jones D, Cox J, Luo B, Cooksey RC, Boros LG, McClain DA.

FASEB J. 2013 Jul;27(7):2845-54. doi: 10.1096/fj.12-216929. Epub 2013 Mar 20.

27.

TRIF is required for TLR4 mediated adjuvant effects on T cell clonal expansion.

Gandhapudi SK, Chilton PM, Mitchell TC.

PLoS One. 2013;8(2):e56855. doi: 10.1371/journal.pone.0056855. Epub 2013 Feb 15.

28.

Immunopharmacology of lipid A mimetics.

Bowen WS, Gandhapudi SK, Kolb JP, Mitchell TC.

Adv Pharmacol. 2013;66:81-128. doi: 10.1016/B978-0-12-404717-4.00003-2. Review.

PMID:
23433456
29.

Effects of Differences in Lipid A Structure on TLR4 Pro-Inflammatory Signaling and Inflammasome Activation.

Chilton PM, Embry CA, Mitchell TC.

Front Immunol. 2012 Jun 13;3:154. doi: 10.3389/fimmu.2012.00154. eCollection 2012.

30.

Selective TRIF-dependent signaling by a synthetic toll-like receptor 4 agonist.

Bowen WS, Minns LA, Johnson DA, Mitchell TC, Hutton MM, Evans JT.

Sci Signal. 2012 Feb 14;5(211):ra13. doi: 10.1126/scisignal.2001963.

31.

Mechanism of impaired NLRP3 inflammasome priming by monophosphoryl lipid A.

Embry CA, Franchi L, Nuñez G, Mitchell TC.

Sci Signal. 2011 May 3;4(171):ra28. doi: 10.1126/scisignal.2001486.

32.

MyD88-dependent SHIP1 regulates proinflammatory signaling pathways in dendritic cells after monophosphoryl lipid A stimulation of TLR4.

Cekic C, Casella CR, Sag D, Antignano F, Kolb J, Suttles J, Hughes MR, Krystal G, Mitchell TC.

J Immunol. 2011 Apr 1;186(7):3858-65. doi: 10.4049/jimmunol.1001034. Epub 2011 Feb 21.

33.

Orally administered particulate beta-glucan modulates tumor-capturing dendritic cells and improves antitumor T-cell responses in cancer.

Li B, Cai Y, Qi C, Hansen R, Ding C, Mitchell TC, Yan J.

Clin Cancer Res. 2010 Nov 1;16(21):5153-64. doi: 10.1158/1078-0432.CCR-10-0820. Epub 2010 Sep 20.

34.

Selective activation of the p38 MAPK pathway by synthetic monophosphoryl lipid A.

Cekic C, Casella CR, Eaves CA, Matsuzawa A, Ichijo H, Mitchell TC.

J Biol Chem. 2009 Nov 13;284(46):31982-91. doi: 10.1074/jbc.M109.046383. Epub 2009 Sep 15.

35.

Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant.

Casella CR, Mitchell TC.

Cell Mol Life Sci. 2008 Oct;65(20):3231-40. doi: 10.1007/s00018-008-8228-6. Review.

36.

Impaired Bcl3 up-regulation leads to enhanced lipopolysaccharide-induced interleukin (IL)-23P19 gene expression in IL-10(-/-) mice.

Mühlbauer M, Chilton PM, Mitchell TC, Jobin C.

J Biol Chem. 2008 May 23;283(21):14182-9. doi: 10.1074/jbc.M709029200. Epub 2008 Mar 28.

37.

Adjuvant induced glucose uptake by activated T cells is not correlated with increased survival.

Sengupta S, Vitale RJ, Chilton PM, Mitchell TC.

Adv Exp Med Biol. 2008;614:65-72. doi: 10.1007/978-0-387-74911-2_8.

PMID:
18290315
38.

The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4.

Mata-Haro V, Cekic C, Martin M, Chilton PM, Casella CR, Mitchell TC.

Science. 2007 Jun 15;316(5831):1628-32.

39.

Unrestrained glycogen synthase kinase-3 beta activity leads to activated T cell death and can be inhibited by natural adjuvant.

Sengupta S, Jayaraman P, Chilton PM, Casella CR, Mitchell TC.

J Immunol. 2007 May 15;178(10):6083-91.

40.

Cutting Edge: Limiting amounts of IL-7 do not control contraction of CD4+ T cell responses.

Tripathi P, Mitchell TC, Finkelman F, Hildeman DA.

J Immunol. 2007 Apr 1;178(7):4027-31.

41.
43.

Peptide-stimulated DO11.10 T cells divide well but accumulate poorly in the absence of TLR agonist treatment.

Thompson BS, Mata-Haro V, Casella CR, Mitchell TC.

Eur J Immunol. 2005 Nov;35(11):3196-208.

44.

The low-toxicity versions of LPS, MPL adjuvant and RC529, are efficient adjuvants for CD4+ T cells.

Thompson BS, Chilton PM, Ward JR, Evans JT, Mitchell TC.

J Leukoc Biol. 2005 Dec;78(6):1273-80. Epub 2005 Oct 4.

PMID:
16204643
45.

Measurement of daughter cell accumulation during lymphocyte proliferation in vivo.

Thompson BS, Mitchell TC.

J Immunol Methods. 2004 Dec;295(1-2):79-87. Epub 2004 Oct 27.

PMID:
15627613
46.

A short domain within Bcl-3 is responsible for its lymphocyte survival activity.

Mitchell TC, Thompson BS, Trent JO, Casella CR.

Ann N Y Acad Sci. 2002 Dec;975:132-47.

PMID:
12538160
47.

Stronger correlation of bcl-3 than bcl-2, bcl-xL, costimulation, or antioxidants with adjuvant-induced T cell survival.

Mitchell TC, Teague TK, Hildeman DA, Bender J, Rees WA, Kedl RM, Swanson B, Kappler JW, Marrack P.

Ann N Y Acad Sci. 2002 Dec;975:114-31.

PMID:
12538159
48.

RANTES production by memory phenotype T cells is controlled by a posttranscriptional, TCR-dependent process.

Swanson BJ, Murakami M, Mitchell TC, Kappler J, Marrack P.

Immunity. 2002 Nov;17(5):605-15.

49.

Activated T cell death in vivo mediated by proapoptotic bcl-2 family member bim.

Hildeman DA, Zhu Y, Mitchell TC, Bouillet P, Strasser A, Kappler J, Marrack P.

Immunity. 2002 Jun;16(6):759-67.

50.

Molecular mechanisms of activated T cell death in vivo.

Hildeman DA, Zhu Y, Mitchell TC, Kappler J, Marrack P.

Curr Opin Immunol. 2002 Jun;14(3):354-9. Review.

PMID:
11973134

Supplemental Content

Loading ...
Support Center